JP7409383B2 - Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形 - Google Patents

Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形 Download PDF

Info

Publication number
JP7409383B2
JP7409383B2 JP2021540972A JP2021540972A JP7409383B2 JP 7409383 B2 JP7409383 B2 JP 7409383B2 JP 2021540972 A JP2021540972 A JP 2021540972A JP 2021540972 A JP2021540972 A JP 2021540972A JP 7409383 B2 JP7409383 B2 JP 7409383B2
Authority
JP
Japan
Prior art keywords
crystal
powder
ray diffraction
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021540972A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021033729A5 (https=
JPWO2021033729A1 (https=
Inventor
修平 大谷
貴之 藤戸
直子 猪村
秀臣 木嶋
ステファン ディー． ペアレント，
メラニー ジャネル ベビル，
コートニー エス． ジョンソン，
トラビス リー ヒューストン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of JPWO2021033729A1 publication Critical patent/JPWO2021033729A1/ja
Publication of JPWO2021033729A5 publication Critical patent/JPWO2021033729A5/ja
Application granted granted Critical
Publication of JP7409383B2 publication Critical patent/JP7409383B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021540972A 2019-08-20 2020-08-19 Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形 Active JP7409383B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962889091P 2019-08-20 2019-08-20
US62/889,091 2019-08-20
PCT/JP2020/031326 WO2021033729A1 (ja) 2019-08-20 2020-08-19 Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形

Publications (3)

Publication Number Publication Date
JPWO2021033729A1 JPWO2021033729A1 (https=) 2021-02-25
JPWO2021033729A5 JPWO2021033729A5 (https=) 2022-09-14
JP7409383B2 true JP7409383B2 (ja) 2024-01-09

Family

ID=74660224

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540972A Active JP7409383B2 (ja) 2019-08-20 2020-08-19 Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形

Country Status (15)

Country Link
US (1) US12459890B2 (https=)
EP (1) EP4019496B1 (https=)
JP (1) JP7409383B2 (https=)
KR (1) KR102930707B1 (https=)
CN (1) CN114302873A (https=)
BR (1) BR112022002632A2 (https=)
CA (1) CA3150303A1 (https=)
ES (1) ES2983098T3 (https=)
IL (1) IL290432A (https=)
MX (1) MX2022001820A (https=)
MY (1) MY207001A (https=)
PH (1) PH12022550319A1 (https=)
TW (1) TWI859303B (https=)
WO (1) WO2021033729A1 (https=)
ZA (1) ZA202201784B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3757091T (pt) * 2018-02-22 2024-09-11 Ono Pharmaceutical Co Ácido 1-[[(3s)-3-metil-6-(4,4,4-trifluorobutoxi)-3,4-di-hidronaftalen-2-il]metil]azetidino-3-carboxílico com atividade agonista do recetor s1p5 para o tratamento de doenças neurodegenerativas e cancro
AU2022291768A1 (en) 2021-06-16 2023-11-30 Celgene Corporation Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases
EP4633736A1 (en) * 2022-12-16 2025-10-22 Celgene Corporation Heterocyclic compounds as modulators of s1p5
WO2025119254A1 (en) * 2023-12-06 2025-06-12 Ono Pharmaceutical Co., Ltd. Method for preparing dihydronaphthalene derivative

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064757A1 (ja) 2004-12-13 2006-06-22 Ono Pharmaceutical Co., Ltd. アミノカルボン酸誘導体およびその医薬用途
JP2009540006A (ja) 2006-06-12 2009-11-19 ノバルティス アクチエンゲゼルシャフト Ｎ−ヒドロキシ−３−［４−［［［２−（２−メチル−１ｈ−インドール−３−イル）エチル］アミノ］メチル］フェニル］−２ｅ−２−プロペンアミドの多形
WO2016088834A1 (ja) 2014-12-04 2016-06-09 小野薬品工業株式会社 ジヒドロナフタレン誘導体
WO2019163917A1 (ja) 2018-02-22 2019-08-29 小野薬品工業株式会社 Ｓ１ｐ５受容体作動活性を有する化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ234564A (en) * 1986-11-21 1991-04-26 Haessle Ab 1-substituted benzimidazoles and pharmaceutical compositions
GB8725118D0 (en) * 1987-10-27 1987-12-02 Ciba Geigy Ag Rifamycin derivatives
JP2005020882A (ja) 2003-06-25 2005-01-20 Matsushita Electric Works Ltd モータアクチュエータ装置
US7825109B2 (en) 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
KR20110140139A (ko) 2003-08-29 2011-12-30 오노 야꾸힝 고교 가부시키가이샤 Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
JP2006064757A (ja) 2004-08-24 2006-03-09 Systec Kyowa:Kk ディスプレイ固定用スタンド
JP2009526073A (ja) 2006-02-09 2009-07-16 ユニバーシティ オブ バージニア パテント ファンデーション 二環式スフィンゴシン−１−リン酸受容体アナログ
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
EA034451B1 (ru) 2011-02-07 2020-02-10 Байоджен Ма Инк. Модуляторы s1p
EP3409658B9 (en) 2016-01-29 2024-07-17 ONO Pharmaceutical Co., Ltd. Tetrahydronaphthalene derivative
TW202114983A (zh) * 2019-08-20 2021-04-16 日商小野藥品工業股份有限公司 Ｓ１ｐ媒介疾病的預防及／或治療劑

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064757A1 (ja) 2004-12-13 2006-06-22 Ono Pharmaceutical Co., Ltd. アミノカルボン酸誘導体およびその医薬用途
JP2009540006A (ja) 2006-06-12 2009-11-19 ノバルティス アクチエンゲゼルシャフト Ｎ−ヒドロキシ−３−［４−［［［２−（２−メチル−１ｈ−インドール−３−イル）エチル］アミノ］メチル］フェニル］−２ｅ−２−プロペンアミドの多形
WO2016088834A1 (ja) 2014-12-04 2016-06-09 小野薬品工業株式会社 ジヒドロナフタレン誘導体
WO2019163917A1 (ja) 2018-02-22 2019-08-29 小野薬品工業株式会社 Ｓ１ｐ５受容体作動活性を有する化合物
JP2023029542A (ja) 2018-02-22 2023-03-03 小野薬品工業株式会社 Ｓ１ｐ５受容体作動活性を有する化合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Pharmaceutical Salts，Journal of Pharmaceutical Sciences，1977年，Vol.66, No.1，p.1-19
小嶌隆史，医薬品開発における結晶性選択の効率化を目指して，薬剤学，2008年09月01日，Vol.68, No.5，p.344-349
芦澤 一英，塩・結晶形の最適化と結晶化技術，Pharm Tech Japan，2002年，Vol. 18, No. 10，pp. 81-96
高田則幸，創薬段階における原薬Formスクリーニングと選択，PHARM STAGE，Vol.6, No.10，2007年01月15日，p.20-25

Also Published As

Publication number Publication date
TWI859303B (zh) 2024-10-21
TW202114984A (zh) 2021-04-16
MY207001A (en) 2025-01-23
EP4019496A4 (en) 2023-01-11
CN114302873A (zh) 2022-04-08
US20220289675A1 (en) 2022-09-15
AU2020334489C1 (en) 2026-03-26
EP4019496A1 (en) 2022-06-29
JPWO2021033729A1 (https=) 2021-02-25
WO2021033729A1 (ja) 2021-02-25
ES2983098T3 (es) 2024-10-22
US12459890B2 (en) 2025-11-04
MX2022001820A (es) 2022-03-17
KR20220050886A (ko) 2022-04-25
AU2020334489A1 (en) 2022-03-03
BR112022002632A2 (pt) 2022-05-03
KR102930707B1 (ko) 2026-02-24
AU2020334489B2 (en) 2025-10-30
IL290432A (en) 2022-04-01
PH12022550319A1 (en) 2022-12-19
EP4019496B1 (en) 2024-06-05
CA3150303A1 (en) 2021-02-25
NZ785003A (en) 2024-09-27
ZA202201784B (en) 2024-02-28

Similar Documents

Publication Publication Date Title
JP7409383B2 (ja) Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形
US20230049327A1 (en) Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JP7035108B2 (ja) プリドピジンの類似体、それらの製造および使用
US20250340558A1 (en) Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
TW201035048A (en) New salt and crystalline forms
EP3409658B1 (en) Tetrahydronaphthalene derivative
WO2014030716A1 (ja) ピラゾロピリミジン化合物
US12049445B2 (en) Compounds having S1P5 receptor agonistic activity
TW200900395A (en) Heteroarylamide pyrimidone compounds
KR20240088949A (ko) 질병 및 질환의 치료를 위한 lsd 유도체, 합성 및 방법
JP6929857B2 (ja) ６，７，８，９−テトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピンドーパミンＤ３リガンド
CN114149423A (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539229A (zh) 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
JP7354960B2 (ja) Ｓ１ｐ５介在性疾患の予防および／または治療剤
TW201713629A (zh) 新穎苯并咪唑化合物及其醫藥用途
WO2021091819A1 (en) Salts and forms of an estrogen receptor modulator
RU2833357C2 (ru) Соль и кристаллическая форма соединения, обладающего агонистической активностью по отношению к рецептору s1p5
TW467914B (en) 2-(aminomethyl)-3,4,7,9-tetrahydro-2h-pyrano-[2,3-e]indol-8-ones and derivatives
HK40069904A (en) Salt and crystal form of compound having agonistic activity to s1p5 receptor
AU2020334489C8 (en) Salt and crystal form of compound having agonistic activity to S1P5 receptor
RU2781541C2 (ru) Соединения, обладающие агонистической активностью по отношению к рецептору s1p5
BR112020017036B1 (pt) Compostos com atividade agonista do receptor esfingosina-1- fosfato de tipo 5 (s1p5), composição farmacêutica que compreende os mesmos e uso dos ditos compostos para prevenir e/ou tratar uma doença mediada por s1p5
EP2340818A1 (en) Co-crystals of venlafaxine and celecoxib
WO2024207945A1 (zh) 作为aak1抑制剂的氮杂环类化合物
WO2019046534A1 (en) INDOLOQUINOLINE COMPOUNDS DEUTTERED

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231204

R150 Certificate of patent or registration of utility model

Ref document number: 7409383

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150